What is the Cystinuria Epidemiology Forecast?

Cystinuria is recognized as the most common inheritable cause of kidney stones, caused by the accumulation of cystine in urine due to defective reabsorption in the kidneys. According to current estimates, the incidence of cystinuria is approximately 1 in 7,000 individuals worldwide, including in the United States. The condition is more prevalent in men, with a male-to-female ratio of 2:1.

The Cystinuria Epidemiology Forecast 2025-2034 provides comprehensive insights into the prevalence, incidence, and demographics of cystinuria, helping healthcare stakeholders, researchers, and pharmaceutical companies understand trends and plan for patient care strategies.

Cystinuria Understanding: Disease Overview

Cystinuria is a rare, inherited disorder leading to the formation of cystine stones in the kidneys, ureters, and bladder. These stones form because cystine, an amino acid, is not properly reabsorbed by the kidneys, resulting in crystallization in the urinary tract.

Common symptoms include:

• Hematuria (blood in urine)

• Flank or loin pain

• Fever during stone episodes

• Vomiting

Impact:

• Cystinuria contributes to recurrent kidney stone formation, affecting the quality of life of patients.

• Though severe cases can occur, renal insufficiency is rare, even in patients with recurrent stones.

Cystinuria Epidemiology Perspective

The epidemiology of cystinuria is studied across eight major global markets:

• United States

• Germany

• France

• Italy

• Spain

• United Kingdom

• Japan

• India

The report examines:

• Total prevalent cases by gender (male and female)

• Diagnosed cases across age groups

• Patterns of recurrence and severity

Global Prevalence Insights

• Estimated prevalence: 1 in 7,000 globally (Orphanet)

• Additional urinary chemical abnormalities: 20%-40% of patients

  • Hypocitraturia: 44%

  • Hypercalciuria: 19%

  • Hyperuricosuria: 22%

• Genetic mutation: The M467T mutation in the SLC3A1 gene, common among Mediterranean populations, accounts for nearly 50% of cases in Spain but is rare elsewhere.

Age-Based Cystinuria Epidemiology Insights

• Cystinuria can manifest at any age, but kidney stones commonly begin forming before age 20.

• The average age of onset is around 15 years, often presenting with renal colic.

• Approximately 22% of patients start developing stones during childhood, highlighting the need for early detection and intervention.

Gender-Based Cystinuria Epidemiology Insights

• Males generally exhibit more severe disease, with some cases showing kidney stones before age 3.

• The male-to-female ratio is consistently reported as 2:1.

• Over 75% of cases involve bilateral stones, and recurrence rates in males exceed 60%.

Observation: While males experience more frequent and severe stones, both genders have a low risk of renal failure when managed appropriately.

Cystinuria Number of Cases by Country

Epidemiology varies across regions due to:

• Genetic predisposition

• Environmental factors

• Dietary habits

• Healthcare infrastructure

Country-specific insights:

• United States: Estimated 1 in 7,000–10,000 individuals affected

• Spain: High prevalence of the SLC3A1 M467T mutation

• Germany, France, Italy, UK, Japan, India: Case numbers are influenced by diagnostic availability and reporting systems

Cystinuria Treatment Overview

Management of cystinuria focuses on preventing stone formation and reducing recurrence.

First-line treatments:

• Increased fluid intake to dilute urine

• Dietary modifications: Reduced animal protein and sodium intake

Pharmacological treatments:

• Cystine-binding thiol drugs like tiopronin (alpha-mercaptopropionylglycine) and D-penicillamine

• Mechanism: These drugs bind to cystine in urine, forming a more soluble complex for easier excretion

Additional care strategies:

• Regular monitoring through imaging to detect early stone formation

• Management of urinary pH levels to reduce crystallization risk

Cystinuria Epidemiology Forecast (2025–2034)

• The forecast period (2025–2034) highlights projected prevalence trends in the eight major markets.

• Key insights:

  • Stable global incidence with gradual increases in diagnosed cases due to better awareness and diagnostic tools

  • Pediatric cases are expected to continue appearing early, requiring ongoing preventive care

  • Male cases remain more frequent and severe, influencing healthcare planning

Discover More Reports

Antimicrobial Hospital Curtains Market

Mastopexy Market

Gas Chromatography Market

Guidewires Market

About Us:

Expert Market Research is a leading market research firm delivering data-driven insights to the pharmaceutical, biotechnology, and medical device industries. Our comprehensive research solutions include market research reports, providing in-depth analysis of industry trends and competitive landscapes; drug pipeline reports, tracking drug development progress, clinical trials, and regulatory approvals; epidemiology reports, offering detailed disease prevalence and patient population studies; and patent reports, assessing intellectual property landscapes and innovation trends, among others.

Leveraging proprietary data, advanced analytics, and expert methodologies, we help businesses navigate complex markets, optimize strategies, and drive innovation. We empower clients with actionable intelligence, enabling them to make informed decisions and stay ahead in the rapidly evolving healthcare sector.

Media Contact:

Company Name: Claight Corporation
Contact Person: Roshan Kumar, Digital Marketing
Email: sales@expertmarketresearch.com
Toll-Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: www.expertmarketresearch.com